Jane Street
INMB icon

Jane Street’s INmune Bio INMB Stock Holding History

Jane Street’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,600
Closed -$206K – 10429
2021
Q3 		$206K Buy
+10,600
New +$205K ﹤0.01% 8794

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street's INMB Position: Q1 2026 in Review

Jane Street increased its INmune Bio (INMB) stake by 122% in Q1 2026, buying an estimated $39.9K and bringing the position to 50,944 shares worth $57.6K. The position accounts for ﹤0.01% of the portfolio, ranked #10913.

Jane Street first reported a position in INMB in Q1 2021 and has held it in 9 quarters since. The position peaked at $869K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Jane Street held 50,944 shares of INmune Bio worth $57.6K as of Q1 2026.
  • Jane Street bought 27,987 INmune Bio shares in Q1 2026, an estimated $39.9K.
  • INmune Bio made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10913 holding.
  • Jane Street first reported a position in INmune Bio in Q1 2021 and has held it in 9 quarters since.
  • Jane Street's INmune Bio position peaked at $869K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.